Thin
Analytical batch testing via RP-HPLC and mass spectrometry ensuring ≥99.0% purity for pharmaceutical R&D and commercial formulation.
A technical examination of cellular bioenergetics, mitochondrial rejuvenation, and clinical-grade synthetic methodologies.
The global demand for high-purity custom peptides is surging exponentially, driven by breakthroughs in GLP-1 receptor agonists like semaglutide, dual/triple co-agonists, and peptide-nucleotide co-formulations. Therapeutic innovators require multi-ton synthetic capacity paired with ultra-low residual TFA and host cell impurity limits to meet stringent global pharmacopeia standards.
Nicotinamide adenine dinucleotide functions not only as a crucial coenzyme in redox reactions but also as a limiting cosubstrate for sirtuins (SIRT1-7) and poly(ADP-ribose) polymerases. Synthesizing stable peptide delivery scaffolds that conjugate with NAD+ precursor systems bypasses hydrolytic breakdown in the gastrointestinal tract, enabling direct cytosolic uptake.
Traditional biological fermentation approaches to nucleotide-peptide conjugates encounter significant challenges regarding deletion sequence co-elution and truncated impurities. Transitioning to advanced Solid-Phase Peptide Synthesis (SPPS) assisted by microwave coupling ensures precise chirality, sequence integrity, and batch reproducibility across high-tonnage production lots.
Combining chemical engineering prowess with multi-ton industrial capacity to overcome global peptide API raw material supply shortages.
Located in the Heda Medicine Valley of Hangzhou, our facility integrates industrial-scale automated peptide synthesizers. With reactors up to 1000L and multi-ton cumulative output, we guarantee seamless transition from gram-scale pilot batches to commercial metric-ton supply, preventing supply chain disruptions.
By producing raw amino acids, specialized Fmoc/Boc protected derivatives, coupling reagents, and crosslinked resins on-site or through local supply ecosystems, our production pipelines remain immune to external component shortages. This yields exceptional lead time stability and unmatched unit-cost economics.
Our downstream purification suite utilizes DAC (Dynamic Axial Compression) chromatography columns ranging from 200mm to 800mm diameter. Paired with industrial freeze-drying lyophilisers, we eliminate complex diastereomeric impurities and guarantee consistent lot-to-lot purity ≥99.0%.
Deploying specialized NAD+ peptides across precision clinical, cosmeceutical, and metabolic treatment pathways.
Synthesized peptide sequences like Semax and Selank, combined with NAD+ precursors, are being evaluated in clinical trial settings across North America and Europe to counter neurodegenerative decline. They promote brain-derived neurotrophic factor (BDNF) expression and preserve microglial bioenergetic integrity.
Topical aesthetic formulations require highly stable lipopeptide conjugates and copper tripeptides (GHK-Cu). When formulated alongside bio-compatible NAD+ derivatives, these compounds trigger collagen I/III biosynthesis, accelerate keratinocyte renewal, and suppress cellular senescence associated with skin photo-aging.
Targeting chronic metabolic disorders via dual and triple incretin receptor agonists (Retatrutide, Mazdutide, Survodutide). Pairing these therapeutic peptides with cellular NAD+ replenishment balances adipokine secretion, reverses hepatic steatosis, and restores baseline glycemic homeostasis.
Strategic technological initiatives driving the next generation of peptide API yield optimization and ecological compliance.
For complex peptides exceeding 30 amino acids (such as GLP-1 and GLP-2 analogues), Thinheal is deploying hybrid Liquid-Phase / Solid-Phase Synthesis. Fragment condensation allows higher atom economy, dramatic reductions in DMF/NMP solvent consumption, and significantly improved single-pass yields.
Leveraging deep learning structural models to predict steric hindrance, spontaneous aggregation, and side-chain racemization during coupling steps. By algorithmically optimizing orthogonal protecting group selection, Thinheal minimizes synthesis cycles and lowers overall impurity burdens.
Looking to 2026 and beyond, Thinheal's R&D team is developing engineered peptide ligases (subtiligase mutants) to catalyze the condensation of unprotected peptide segments in aqueous media. This minimizes environmental impact while generating high-potency cyclic and conjugated peptide active substances.
Comprehensive qualification documentation enabling frictionless auditing for US FDA, EMA, NMPA, and PMDA filings.
Every commercial batch is accompanied by comprehensive Certificates of Analysis (CoA), complete with High-Performance Liquid Chromatography (RP-HPLC) traces, Electrospray Ionization Mass Spectrometry (ESI-MS), Karl Fischer water titration, amino acid profiling, and residual acetate/TFA quantification.
Recognizing the temperature sensitivity of lyophilized peptides and liquid intermediates, our international export division maintains cold-chain integrity via dry ice or monitored 2–8°C validated insulation packaging with calibrated real-time data loggers for global airfreight transit.
Dedicated regional account teams provide native language support across four major trading corridors: USA & Europe, Russia & CIS, Asia-Pacific, and the Middle East, guaranteeing real-time technical answers within 12 business hours.
Ready-to-ship reference standards, API synthesis intermediates, and specialized metabolic regulatory peptides.
In-depth responses covering synthesis chemistry, purity limits, scale-up protocols, and quotation terms.
Every commercial batch is accompanied by comprehensive Certificates of Analysis (CoA) containing individual analytical data: RP-HPLC chromatograms showing relative retention times and impurity profiles, high-resolution ESI-MS or MALDI-TOF spectra verifying exact molecular mass, residual moisture via Karl Fischer titration, net peptide content via nitrogen analysis, and residual trifluoroacetic acid (TFA) or acetate counter-ion quantification.
We deploy optimized pseudoproline dipeptides, microwave-assisted coupling, and specialized sterically hindered resins. Coupling completeness is monitored at every single elongation step via automated Kaiser or chloranil testing. Downstream, preparative DAC reverse-phase HPLC systems utilizing non-linear gradient elution guarantee the absolute removal of closely eluting truncated sequences.
Standard technical feasibility reviews and formal commercial quotations are provided within 24 to 48 hours. For custom synthesis sequences under 30 amino acids at gram to multi-kilogram scale, pilot batch synthesis, purification, lyophilization, and release testing are completed within 2 to 4 weeks. Multi-ton generic API delivery schedules are determined via dedicated client master supply agreements.
Yes. While peptides synthesized via classic SPPS typically elute with trifluoroacetic acid (TFA) as the primary counter-ion, Thinheal offers ion-exchange chromatography steps to convert APIs into physiological acetate or hydrochloride salt forms, keeping residual TFA concentrations well within ICH Q3D limits (<0.1% or undetectable).
Our manufacturing base operates in strict alignment with cGMP protocols, featuring segregated class D to class A cleanroom environments, dedicated clean utilities (Water for Injection and Clean Steam), and a qualified computerized Quality Management System (QMS). Validated cleaning procedures and fully automated clean-in-place (CIP) and sterilize-in-place (SIP) cycles prevent any cross-contamination across continuous multi-ton campaigns.